News

The company said that the updated breakthrough therapy designation reflects recently presented data on HCV genotype 1 patients with advanced cirrhosis (Child-Pugh Class B or C) and those

Currently, Revusiran is being evaluated in a Phase III trial to treat Familial Amyloidotic Cardiomyopathy (FAC), one of the predominant clinical manifestations of ATTR amyloidosis. Patient enrollment is

In Japan, Lenvima is the first molecular targeted treatment approved with an indication for unresectable thyroid cancer which covers differentiated thyroid cancer as well as medullary thyroid carcinoma

This study demonstrated that Latuda (lurasidone HCl) significantly reduced depressive symptoms in adults with MDD with mixed features when compared to placebo. The study results were presented at

The Muscle Maker Grill booster supplements are intended to meet the growing consumer demand for customized smoothies and protein shakes as well as help Muscle Maker Grill franchisees

"Emergent is pleased to enter into this agreement, which reflects our leading capabilities in plasma fractionation and fits perfectly with ProMetic’s proprietary plasma purification platform," said Barry Labinger,

Under the agreement, DNAtrix will utilize Alcyone’s MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix’s lead product for the

A significant percentage ofobese patients do not progress to full cure after antibiotictreatment is completed. Among obese patients whose infection wasnot fully cured at late follow-up, health-related quality

Under the deal, the OCTC will provide integrated research, clinical trial and core lab services, while Bryla will provide commercialization services in chemistry, manufacturing and control (CMC). Bryla